This Phase I trial will identify the maximum tolerated dose of Thymitaq (AG337) in patients with advanced solid tumors, assess the toxicity of Thymitaq administered sequentially with cisplatin, and determine whether the administration of cisplatin alters the clearance of Thymitaq.
Showing the most recent 10 out of 600 publications